Image Source: Istock
Fall brings new challenges for pharmacies, especially with the upcoming cold and flu season.
Image Source: Istock
CVS and Walgreens workers have protested against working conditions, creating labor issues.
Image Source: Istock
The FDA found oral phenylephrine to be ineffective against cold and flu symptoms.
Image Source: Istock
Not all cold medicines are affected; those with phenylephrine plus other ingredients remain effective.
Image Source: Istock
CVS proactively removes cold meds with oral phenylephrine as the sole active ingredient.
Image Source: Istock
Rite Aid's response to the situation is pending, while Walgreens closely monitors the developments.
Image Source: Istock
FDA's findings could impact pharmacies' revenues, as $1.8 billion worth of phenylephrine products were sold last year.
Image Source: Istock
CVS Health removes decongestants containing oral phenylephrine from its shelves.
Image Source: Istock
Sanofi's Lantus insulin will sell for $35 a month through GoodRx, benefiting both insured and uninsured patients.
Image Source: Istock
Hearing spotlights President Biden's NIH nominee, with a central focus on addressing soaring drug prices.
Image Source: Istock
Walgreens settles a class action lawsuit with Rite Aid investors for $192.5 million.
Image Source: Istock
Laronde, an RNA medicines startup, successfully resolves data integrity issues and proceeds with a merger.
Image Source: Istock
Making medicines greener is a challenge due to emissions in the supply chain and patient usage.
Image Source: Istock
Pharmaceuticals contribute significantly to healthcare industry greenhouse gas emissions.
Image Source: Istock
Scope 3 emissions are difficult to reduce, as they involve external suppliers and energy-intensive processes.